ABVC BioPharma receives U.S. patent for ADHD treatment

ABVC BioPharma announced that it received a U.S. patent, Application No. 17/120,965, for the use of PDC-1421, a Radix Polygala extract, which is used in the Company’s asset ABV-1505, targeting Attention Deficit/Hyperactivity Disorder, ADHD. “This patent grants ABVC the right to exclude others from using, offering, or selling PDC-1421 throughout the United States until 2040,” said Dr. Uttam Patil, ABVC Chief Executive Officer. “As we work towards expanding our patent map into global coverage, we eagerly await the results of patent applications in the European Union, China, Japan, and others.” ABVC submitted the patent application to the United States Patent and Trademark Office under “Polygala Extract for the Treatment of ADHD.” The invention relates to oral administration of the formulation containing a Radix Polygala extract, PDC-1421, as a capsule for treating ADHD. Based on current studies, the composition should be administered three times a day for eight weeks; each dose ranges between 380-760 mg of the botanical extraction.